UROsphere and Vectalys (a company specialized in viral vector production and cell transduction expertises for gene discovery and validation) are pleased to announce the selection of the research programme « Discovery of new targets for prostatic pathologies ». This programme has been retained through an innovative project call organized by SISMIP (Health Industries Network in the Midi-Pyrenees Region) and DRIRE Midi-Pyrenees (Regional Board for Industries, Research and Environment). Both companies will work together on the programme for 1 year.
UROsphere announces that OSEO Innovation has awarded a grant over a 2-year period to expand its experimental research platform for early stage drug development. The funding will be used to develop innovative in vivo and in vitro models to offer a wider range of assays for genitourinary pathologies.
OSEO innovation (France's national agency for industrial innovation) funds innovative, technology-oriented projects for commercialization in France and abroad.
More infosUROsphere cible les pathologies génitourinaires. (Gazette du Laboratoire, Mai 2007)
More infos"Prostatic enlargment and inflamation" is a well estalished model for BPH in rats.
UROsphere s'associe au SISMIP, le groupement des industries de la santé en Midi-Pyrénées.
UROsphere en pleine croissance. (Actu Labo, 24/01/07)
UROsphere parcourt la planète. (supplément Eco de la Depêche du Midi, 11/11/2006)
UROsphere sélectionné parmi les 110 entreprises innovantes en France.
Dossier des Jeunes Entreprises Innovantes (Usine Nouvelle, 02 Fev 2006)